{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:19:55Z","timestamp":1792793995135,"version":"4.5.0"},"reference-count":52,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2019,5,2]],"date-time":"2019-05-02T00:00:00Z","timestamp":1556755200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010198","name":"Ministerio de Econom\u00eda, Industria y Competitividad, Gobierno de Espa\u00f1a","doi-asserted-by":"publisher","award":["2017-83267-C2-1-R"],"award-info":[{"award-number":["2017-83267-C2-1-R"]}],"id":[{"id":"10.13039\/501100010198","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"Fundaci\u00f3n Cient\u00edfica Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer","doi-asserted-by":"publisher","award":["NK grant"],"award-info":[{"award-number":["NK grant"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fundaci\u00f3n BBVA","award":["BBVA award"],"award-info":[{"award-number":["BBVA award"]}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["PROCROP"],"award-info":[{"award-number":["PROCROP"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40425-019-0568-2","type":"journal-article","created":{"date-parts":[[2019,5,2]],"date-time":"2019-05-02T10:04:23Z","timestamp":1556791463000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":127,"title":["Immunotherapeutic effects of intratumoral nanoplexed poly I:C"],"prefix":"10.1136","volume":"7","author":[{"given":"M. Angela","family":"Aznar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lourdes","family":"Planelles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"Perez-Olivares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saray","family":"Garasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I\u00f1aki","family":"Etxeberr\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiomar","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elixabet","family":"Bola\u00f1os","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Lopez-Casas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria E.","family":"Rodriguez-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose L.","family":"Perez-Gracia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Marquez-Rodas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro","family":"Teijeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisol","family":"Quintero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1360-348X","authenticated-orcid":false,"given":"Ignacio","family":"Melero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,5,2]]},"reference":[{"issue":"1","key":"568_CR1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.4049\/jimmunol.1601145","volume":"198","author":"MA Aznar","year":"2017","unstructured":"Aznar MA, Tinari N, Rullan AJ, Sanchez-Paulete AR, Rodriguez-Ruiz ME, Melero I. Intratumoral delivery of immunotherapy-act locally, Think Globally. J Immunol. 2017;198(1):31\u20139.","journal-title":"J Immunol"},{"issue":"3","key":"568_CR2","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.ctrv.2005.03.004","volume":"31","author":"JM Kaminski","year":"2005","unstructured":"Kaminski JM, Shinohara E, Summers JB, Niermann KJ, Morimoto A, Brousal J. The controversial abscopal effect. Cancer Treat Rev. 2005;31(3):159\u201372.","journal-title":"Cancer Treat Rev"},{"issue":"7","key":"568_CR3","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1158\/1078-0432.CCR-13-2116","volume":"20","author":"A Marabelle","year":"2014","unstructured":"Marabelle A, Kohrt H, Caux C, Levy R. Intratumoral immunization: a new paradigm for cancer therapy. Clin Cancer Res. 2014;20(7):1747\u201356.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"568_CR4","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/BF01741599","volume":"33","author":"RA Maas","year":"1991","unstructured":"Maas RA, Van Weering DH, Dullens HF, Den Otter W. Intratumoral low-dose interleukin-2 induces rejection of distant solid tumour. Cancer Immunol Immunother. 1991;33(6):389\u201394.","journal-title":"Cancer Immunol Immunother"},{"issue":"8","key":"568_CR5","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/sj.cgt.7701064","volume":"14","author":"DM Mahvi","year":"2007","unstructured":"Mahvi DM, Henry MB, Albertini MR, Weber S, Meredith K, Schalch H, et al. Intratumoral injection of IL-12 plasmid DNA--results of a phase I\/IB clinical trial. Cancer Gene Ther. 2007;14(8):717\u201323.","journal-title":"Cancer Gene Ther"},{"issue":"13","key":"568_CR6","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.1158\/1078-0432.CCR-15-2709","volume":"22","author":"PA Ott","year":"2016","unstructured":"Ott PA, Hodi FS. Talimogene Laherparepvec for the treatment of advanced melanoma. Clin Cancer Res. 2016;22(13):3127\u201331.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"568_CR7","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nm.3089","volume":"19","author":"J Heo","year":"2013","unstructured":"Heo J, Reid T, Ruo L, Breitbach CJ, Rose S, Bloomston M, et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med. 2013;19(3):329\u201336.","journal-title":"Nat Med"},{"issue":"11","key":"568_CR8","doi-asserted-by":"publisher","DOI":"10.4161\/onci.26493","volume":"2","author":"MF Fransen","year":"2013","unstructured":"Fransen MF, Ossendorp F, Arens R, Melief CJ. Local immunomodulation for cancer therapy: providing treatment where needed. Oncoimmunology. 2013;2(11):e26493.","journal-title":"Oncoimmunology."},{"issue":"28","key":"568_CR9","doi-asserted-by":"publisher","first-page":"4324","DOI":"10.1200\/JCO.2010.28.9793","volume":"28","author":"JD Brody","year":"2010","unstructured":"Brody JD, Ai WZ, Czerwinski DK, Torchia JA, Levy M, Advani RH, et al. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I\/II study. J Clin Oncol. 2010;28(28):4324\u201332.","journal-title":"J Clin Oncol"},{"issue":"5","key":"568_CR10","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1093\/annonc\/mdy089","volume":"29","author":"ME Rodriguez-Ruiz","year":"2018","unstructured":"Rodriguez-Ruiz ME, Perez-Gracia JL, Rodriguez I, Alfaro C, Onate C, Perez G, et al. Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients. Ann Oncol. 2018;29(5):1312\u20139.","journal-title":"Ann Oncol"},{"issue":"426","key":"568_CR11","doi-asserted-by":"publisher","first-page":"eaan4488","DOI":"10.1126\/scitranslmed.aan4488","volume":"10","author":"Idit Sagiv-Barfi","year":"2018","unstructured":"Sagiv-Barfi I, et al. Eradication of spontaneous malignancy by local immunotherapy. Sci Transl Med. 2018;10(426). https:\/\/doi.org\/10.1126\/scitranslmed.aan4488","journal-title":"Science Translational Medicine"},{"issue":"5","key":"568_CR12","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/ni.1863","volume":"11","author":"T Kawai","year":"2010","unstructured":"Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on toll-like receptors. Nat Immunol. 2010;11(5):373\u201384.","journal-title":"Nat Immunol"},{"key":"568_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1196\/annals.1443.020","volume":"1143","author":"T Kawai","year":"2008","unstructured":"Kawai T, Akira S. Toll-like receptor and RIG-I-like receptor signaling. Ann N Y Acad Sci. 2008;1143:1\u201320.","journal-title":"Ann N Y Acad Sci"},{"issue":"4","key":"568_CR14","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1089\/jir.1983.3.417","volume":"3","author":"Y Riviere","year":"1983","unstructured":"Riviere Y, Hovanessian A. Response of L-1210 tumor in mice toward treatment with interferon or poly(I) X poly(C). J Interf Res. 1983;3(4):417\u201324.","journal-title":"J Interf Res"},{"issue":"2","key":"568_CR15","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1093\/infdis\/121.2.196","volume":"121","author":"MR Hilleman","year":"1970","unstructured":"Hilleman MR. Prospects for the use of double-stranded ribonucleic acid (poly I:C) inducers in man. J Infect Dis. 1970;121(2):196\u2013211.","journal-title":"J Infect Dis"},{"issue":"8","key":"568_CR16","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1158\/2326-6066.CIR-14-0219","volume":"3","author":"R Takemura","year":"2015","unstructured":"Takemura R, Takaki H, Okada S, Shime H, Akazawa T, Oshiumi H, et al. PolyI:C-induced, TLR3\/RIP3-dependent necroptosis backs up immune effector-mediated tumor elimination in vivo. Cancer Immunol Res. 2015;3(8):902\u201314.","journal-title":"Cancer Immunol Res."},{"issue":"1","key":"568_CR17","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1158\/2159-8290.CD-15-0510","volume":"6","author":"AR Sanchez-Paulete","year":"2016","unstructured":"Sanchez-Paulete AR, Cueto FJ, Martinez-Lopez M, Labiano S, Morales-Kastresana A, Rodriguez-Ruiz ME, et al. Cancer immunotherapy with immunomodulatory anti-CD137 and anti-PD-1 monoclonal antibodies requires BATF3-dependent dendritic cells. Cancer Discov. 2016;6(1):71\u20139.","journal-title":"Cancer Discov"},{"issue":"5","key":"568_CR18","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s00262-011-0984-8","volume":"60","author":"SM Amos","year":"2011","unstructured":"Amos SM, Pegram HJ, Westwood JA, John LB, Devaud C, Clarke CJ, et al. Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in mice. Cancer Immunol Immunother. 2011;60(5):671\u201383.","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"568_CR19","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1586\/14760584.2015.966085","volume":"14","author":"KA Martins","year":"2015","unstructured":"Martins KA, Bavari S, Salazar AM. Vaccine adjuvant uses of poly-IC and derivatives. Expert Rev Vaccines. 2015;14(3):447\u201359.","journal-title":"Expert Rev Vaccines"},{"issue":"23","key":"568_CR20","doi-asserted-by":"publisher","first-page":"6497","DOI":"10.1158\/1078-0432.CCR-12-2189","volume":"18","author":"P Sabbatini","year":"2012","unstructured":"Sabbatini P, Tsuji T, Ferran L, Ritter E, Sedrak C, Tuballes K, et al. Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clin Cancer Res. 2012;18(23):6497\u2013508.","journal-title":"Clin Cancer Res"},{"issue":"17","key":"568_CR21","doi-asserted-by":"publisher","first-page":"7945","DOI":"10.1158\/0008-5472.CAN-07-1652","volume":"67","author":"E Celis","year":"2007","unstructured":"Celis E. Toll-like receptor ligands energize peptide vaccines through multiple paths. Cancer Res. 2007;67(17):7945\u20137.","journal-title":"Cancer Res"},{"issue":"7662","key":"568_CR22","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature22991","volume":"547","author":"PA Ott","year":"2017","unstructured":"Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017;547(7662):217\u201321.","journal-title":"Nature."},{"issue":"4","key":"568_CR23","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1093\/infdis\/166.4.717","volume":"166","author":"JA Armstrong","year":"1992","unstructured":"Armstrong JA, McMahon D, Huang XL, Pazin GJ, Gupta P, Rinaldo CR Jr, et al. A phase I study of ampligen in human immunodeficiency virus-infected subjects. J Infect Dis. 1992;166(4):717\u201322.","journal-title":"J Infect Dis"},{"issue":"3","key":"568_CR24","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1097\/01.cji.0000156828.75196.0d","volume":"28","author":"ML Salem","year":"2005","unstructured":"Salem ML, Kadima AN, Cole DJ, Gillanders WE. Defining the antigen-specific T-cell response to vaccination and poly(I:C)\/TLR3 signaling: evidence of enhanced primary and memory CD8 T-cell responses and antitumor immunity. J Immunother. 2005;28(3):220\u20138.","journal-title":"J Immunother"},{"issue":"24","key":"568_CR25","doi-asserted-by":"publisher","first-page":"5119","DOI":"10.1016\/j.vaccine.2006.04.010","volume":"24","author":"ML Salem","year":"2006","unstructured":"Salem ML, El-Naggar SA, Kadima A, Gillanders WE, Cole DJ. The adjuvant effects of the toll-like receptor 3 ligand polyinosinic-cytidylic acid poly (I:C) on antigen-specific CD8+ T cell responses are partially dependent on NK cells with the induction of a beneficial cytokine milieu. Vaccine. 2006;24(24):5119\u201332.","journal-title":"Vaccine."},{"issue":"2","key":"568_CR26","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1158\/1078-0432.CCR-14-1790","volume":"21","author":"H Okada","year":"2015","unstructured":"Okada H, Butterfield LH, Hamilton RL, Hoji A, Sakaki M, Ahn BJ, et al. Induction of robust type-I CD8+ T-cell responses in WHO grade 2 low-grade glioma patients receiving peptide-based vaccines in combination with poly-ICLC. Clin Cancer Res. 2015;21(2):286\u201394.","journal-title":"Clin Cancer Res"},{"key":"568_CR27","doi-asserted-by":"crossref","unstructured":"Rodas IM, Ruiz MER, Cobo SL-T, Gracia JLP, Sarvise MP, Alvarez R, et al. LBA20Safety and immunobiological activity of intratumoral (IT) double-stranded RNA (dsRNA) BO-112 in solid malignancies: First in human clinical trial. Annals of Oncology. 2017;28(suppl_5):mdx440.013-mdx440.013.","DOI":"10.1093\/annonc\/mdx440.013"},{"issue":"12","key":"568_CR28","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1084\/jem.20111171","volume":"208","author":"M Caskey","year":"2011","unstructured":"Caskey M, Lefebvre F, Filali-Mouhim A, Cameron MJ, Goulet JP, Haddad EK, et al. Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans. J Exp Med. 2011;208(12):2357\u201366.","journal-title":"J Exp Med"},{"issue":"8","key":"568_CR29","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1158\/2326-6066.CIR-14-0024","volume":"2","author":"AM Salazar","year":"2014","unstructured":"Salazar AM, Erlich RB, Mark A, Bhardwaj N, Herberman RB. Therapeutic in situ autovaccination against solid cancers with intratumoral poly-ICLC: case report, hypothesis, and clinical trial. Cancer Immunol Res. 2014;2(8):720\u20134.","journal-title":"Cancer Immunol Res"},{"issue":"3","key":"568_CR30","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1200\/JCO.2010.30.7744","volume":"29","author":"H Okada","year":"2011","unstructured":"Okada H, Kalinski P, Ueda R, Hoji A, Kohanbash G, Donegan TE, et al. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol. 2011;29(3):330\u20136.","journal-title":"J Clin Oncol"},{"issue":"2","key":"568_CR31","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ccr.2009.07.004","volume":"16","author":"D Tormo","year":"2009","unstructured":"Tormo D, Checinska A, Alonso-Curbelo D, Perez-Guijarro E, Canon E, Riveiro-Falkenbach E, et al. Targeted activation of innate immunity for therapeutic induction of autophagy and apoptosis in melanoma cells. Cancer Cell. 2009;16(2):103\u201314.","journal-title":"Cancer Cell"},{"issue":"1","key":"568_CR32","doi-asserted-by":"publisher","first-page":"148","DOI":"10.4161\/auto.6.1.10464","volume":"6","author":"D Alonso-Curbelo","year":"2010","unstructured":"Alonso-Curbelo D, Soengas MS. Self-killing of melanoma cells by cytosolic delivery of dsRNA: wiring innate immunity for a coordinated mobilization of endosomes, autophagosomes and the apoptotic machinery in tumor cells. Autophagy. 2010;6(1):148\u201350.","journal-title":"Autophagy."},{"issue":"5904","key":"568_CR33","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1126\/science.1164206","volume":"322","author":"K Hildner","year":"2008","unstructured":"Hildner K, Edelson BT, Purtha WE, Diamond M, Matsushita H, Kohyama M, et al. Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. Science. 2008;322(5904):1097\u2013100.","journal-title":"Science."},{"issue":"2","key":"568_CR34","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1084\/jem.20090851","volume":"207","author":"C Schilte","year":"2010","unstructured":"Schilte C, Couderc T, Chretien F, Sourisseau M, Gangneux N, Guivel-Benhassine F, et al. Type I IFN controls chikungunya virus via its action on nonhematopoietic cells. J Exp Med. 2010;207(2):429\u201342.","journal-title":"J Exp Med"},{"issue":"4","key":"568_CR35","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gng015","volume":"31","author":"RA Irizarry","year":"2003","unstructured":"Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 2003;31(4):e15.","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"568_CR36","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic acids res. 2015;43(7):e47.","journal-title":"Nucleic acids res"},{"issue":"10","key":"568_CR37","doi-asserted-by":"publisher","first-page":"R80","DOI":"10.1186\/gb-2004-5-10-r80","volume":"5","author":"RC Gentleman","year":"2004","unstructured":"Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004;5(10):R80.","journal-title":"Genome Biol"},{"issue":"8","key":"568_CR38","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, et al. IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017;127(8):2930\u201340.","journal-title":"J Clin Invest"},{"key":"568_CR39","unstructured":"Haymaker C, Uemura M, Hwu W, Murthy R, James M, Bhatta A, et al. TLR9 agonist harnesses innate immunity to drive tumor-infiltrating T-cell expansion in distant lesions in a phase 1\/2 study of intratumoral IMO-2125+ipilimumab in anti-PD1 refractory melanoma patients. (018). SITC 2017 Annual meeting November 8-12, 2017; National Harbor,MD, 2017."},{"issue":"20","key":"568_CR40","doi-asserted-by":"publisher","first-page":"5994","DOI":"10.1158\/0008-5472.CAN-16-0549","volume":"76","author":"ME Rodriguez-Ruiz","year":"2016","unstructured":"Rodriguez-Ruiz ME, Rodriguez I, Garasa S, Barbes B, Solorzano JL, Perez-Gracia JL, et al. Abscopal effects of radiotherapy are enhanced by combined Immunostimulatory mAbs and are dependent on CD8 T cells and Crosspriming. Cancer Res. 2016;76(20):5994\u20136005.","journal-title":"Cancer Res"},{"issue":"12","key":"568_CR41","doi-asserted-by":"publisher","first-page":"e1386829","DOI":"10.1080\/2162402X.2017.1386829","volume":"6","author":"AD Garg","year":"2017","unstructured":"Garg AD, More S, Rufo N, Mece O, Sassano ML, Agostinis P, et al. Trial watch: immunogenic cell death induction by anticancer chemotherapeutics. Oncoimmunology. 2017;6(12):e1386829.","journal-title":"Oncoimmunology."},{"issue":"2","key":"568_CR42","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nri.2016.107","volume":"17","author":"L Galluzzi","year":"2017","unstructured":"Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G. Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol. 2017;17(2):97\u2013111.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"568_CR43","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2017-06-741041","volume":"131","author":"C Chester","year":"2018","unstructured":"Chester C, Sanmamed MF, Wang J, Melero I. Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies. Blood. 2018;131(1):49\u201357.","journal-title":"Blood."},{"issue":"6382","key":"568_CR44","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350\u20135.","journal-title":"Science."},{"issue":"2","key":"568_CR45","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/0042-6822(85)90140-0","volume":"147","author":"KA Kelley","year":"1985","unstructured":"Kelley KA, Pitha PM. Differential effect of poly rI.rC and Newcastle disease virus on the expression of interferon and cellular genes in mouse cells. Virology. 1985;147(2):382\u201393.","journal-title":"Virology."},{"issue":"7","key":"568_CR46","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.addr.2007.11.005","volume":"60","author":"M Matsumoto","year":"2008","unstructured":"Matsumoto M, Seya T. TLR3: interferon induction by double-stranded RNA including poly(I:C). Adv Drug Deliv Rev. 2008;60(7):805\u201312.","journal-title":"Adv Drug Deliv Rev"},{"issue":"25","key":"568_CR47","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","volume":"33","author":"RH Andtbacka","year":"2015","unstructured":"Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, et al. Talimogene Laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33(25):2780\u20138.","journal-title":"J Clin Oncol"},{"issue":"suppl_12","key":"568_CR48","doi-asserted-by":"publisher","first-page":"xii44","DOI":"10.1093\/annonc\/mdx237","volume":"28","author":"AR Sanchez-Paulete","year":"2017","unstructured":"Sanchez-Paulete AR, Teijeira A, Cueto FJ, Garasa S, Perez-Gracia JL, Sanchez-Arraez A, et al. Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy. Ann Oncol. 2017;28(suppl_12):xii44\u201355.","journal-title":"Ann Oncol"},{"issue":"3","key":"568_CR49","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2217\/imt.15.120","volume":"8","author":"L Hammerich","year":"2016","unstructured":"Hammerich L, Bhardwaj N, Kohrt HE, Brody JD. In situ vaccination for the treatment of cancer. Immunotherapy. 2016;8(3):315\u201330.","journal-title":"Immunotherapy."},{"issue":"7","key":"568_CR50","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/j.celrep.2015.04.031","volume":"11","author":"L Corrales","year":"2015","unstructured":"Corrales L, Glickman LH, McWhirter SM, Kanne DB, Sivick KE, Katibah GE, et al. Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Rep. 2015;11(7):1018\u201330.","journal-title":"Cell Rep"},{"issue":"8","key":"568_CR51","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nrc3973","volume":"15","author":"I Melero","year":"2015","unstructured":"Melero I, Berman DM, Aznar MA, Korman AJ, Perez Gracia JL, Haanen J. Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer. 2015;15(8):457\u201372.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"568_CR52","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","volume":"170","author":"A Ribas","year":"2017","unstructured":"Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, et al. Oncolytic Virotherapy promotes Intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell. 2017;170(6):1109\u201319 e10.","journal-title":"Cell."}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0568-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40425-019-0568-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0568-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T13:44:13Z","timestamp":1601041453000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-019-0568-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,2]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["568"],"URL":"https:\/\/doi.org\/10.1186\/s40425-019-0568-2","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,2]]},"assertion":[{"value":"7 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MQ, LP, PLC and MPO are full time employees in Bioncotech. IM reports receiving commercial research grants from BMS, Alligator and Roche and serves as a consultant\/advisory board member for BMS, Merck-Serono, Roche-Genentech, Genmab, Incyte, Bioncotech, Tusk, Numab, Genmab, Molecular partners, F-STAR, Alligator, Bayer and AstraZeneca.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"116"}}